BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29555966)

  • 1. Triple-negative breast cancers - a panoply of cancer types.
    Pareja F; Reis-Filho JS
    Nat Rev Clin Oncol; 2018 Jun; 15(6):347-348. PubMed ID: 29555966
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer.
    Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y
    Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
    Rayson D; Lupichuk S; Potvin K; Dent S; Shenkier T; Dhesy-Thind S; Ellard SL; Prady C; Salim M; Farmer P; Allo G; Tsao MS; Allan A; Ludkovski O; Bonomi M; Tu D; Hagerman L; Goodwin R; Eisenhauer E; Bradbury P
    Breast Cancer Res Treat; 2016 May; 157(1):109-16. PubMed ID: 27116183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India.
    ; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP
    Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classifying Breast Cancer Subtypes Using Multiple Kernel Learning Based on Omics Data.
    Tao M; Song T; Du W; Han S; Zuo C; Li Y; Wang Y; Yang Z
    Genes (Basel); 2019 Mar; 10(3):. PubMed ID: 30866472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in breast cancer prognosis: molecular predictors of treatment response and survival.
    Foo EM; Boost MV; Wong AS; Loo WT; Chow LW; Chow CY
    Int J Biol Markers; 2013 Jun; 28(2):131-40. PubMed ID: 23709349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
    Ryu JM; Yu J; Kim SI; Kim KS; Moon HG; Choi JE; Jeong J; Do Byun K; Nam SJ; Lee JE; Lee SK; Kim SW
    Breast Cancer Res Treat; 2017 Dec; 166(3):833-842. PubMed ID: 28831642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of triple-negative breast cancer.
    Kumar P; Aggarwal R
    Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Breast pathology 2014].
    Kreipe HH
    Pathologe; 2014 Feb; 35(1):5-6. PubMed ID: 24496989
    [No Abstract]   [Full Text] [Related]  

  • 12. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
    Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W
    Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hispanic landscape of triple negative breast cancer.
    Zevallos A; Bravo L; Bretel D; Paez K; Infante U; Cárdenas N; Alvarado H; Posada AM; Pinto JA
    Crit Rev Oncol Hematol; 2020 Nov; 155():103094. PubMed ID: 33027724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers.
    Mohamad Hanif EA; Shah SA
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3341-3351. PubMed ID: 30583339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of triple negative breast cancer for surgical oncologists.
    Sharma S; Barry M; Gallagher DJ; Kell M; Sacchini V
    Surg Oncol; 2015 Sep; 24(3):276-83. PubMed ID: 26092709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management.
    Lin NU; Gaspar LE; Soffietti R
    Am Soc Clin Oncol Educ Book; 2017; 37():45-56. PubMed ID: 28561683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organized screening detects breast cancer at earlier stage regardless of molecular phenotype.
    Holloway CMB; Jiang L; Whitehead M; Racz JM; Groome PA
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1769-1775. PubMed ID: 29909564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationally Designed Ruthenium Complexes for Breast Cancer Therapy.
    Golbaghi G; Castonguay A
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31936496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.
    Titloye NA; Foster A; Omoniyi-Esan GO; Komolafe AO; Daramola AO; Adeoye OA; Adisa AO; Manoharan A; Pathak D; D'Cruz MN; Alizadeh Y; Lewis PD; Shaaban AM
    Pathobiology; 2016; 83(1):24-32. PubMed ID: 26730581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.